Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
The Journal of General Virology
|
April 1, 1988
The outer capsid glycoprotein VP7 of simian rotavirus SA11 contains two distinct neutralization epitopes
G Gerna, A Sarasini, A di Matteo, et al.
Journal of Medical Virology
|
July 1, 1990
Nosocomial outbreak of neonatal gastroenteritis caused by a new serotype 4, subtype 4B human rotavirus
G Gerna, J Forster, M Parea, et al.
The Journal of Infectious Diseases
|
September 9, 1999
Prenatal diagnostic and prognostic value of human cytomegalovirus load and IgM antibody response in blood of congenitally infected fetuses
M Grazia Revello, M Zavattoni, A Sarasini, et al.
The New Microbiologica
|
November 11, 1999
Diagnostic value of viral culture, polymerase chain reaction and western blot for HIV-1 infection in 218 infants born to HIV-infected mothers and examined at different ages
E Cattaneo, M Zavattoni, F Baldanti, et al.
Journal of Clinical Microbiology
|
June 1, 1990
Serotype 3 human rotavirus strains with subgroup I specificity
G Gerna, A Sarasini, A Di Matteo, et al.
Journal of Virology
|
February 1, 1995
A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate
F Baldanti, E Silini, A Sarasini, et al.
ESMO Open
|
April 15, 2022
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
A Lasagna, F Bergami, D Lilleri, et al.
ESMO Open
|
August 27, 2022
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
A Lasagna, F Bergami, D Lilleri, et al.
ESMO Open
|
January 1, 2022
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
A Lasagna, D Lilleri, F Agustoni, et al.
ESMO Open
|
September 20, 2021
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
A Lasagna, F Agustoni, E Percivalle, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
The Journal of General Virology
|
April 1, 1988
The outer capsid glycoprotein VP7 of simian rotavirus SA11 contains two distinct neutralization epitopes
G Gerna, A Sarasini, A di Matteo, et al.
Journal of Medical Virology
|
July 1, 1990
Nosocomial outbreak of neonatal gastroenteritis caused by a new serotype 4, subtype 4B human rotavirus
G Gerna, J Forster, M Parea, et al.
The Journal of Infectious Diseases
|
September 9, 1999
Prenatal diagnostic and prognostic value of human cytomegalovirus load and IgM antibody response in blood of congenitally infected fetuses
M Grazia Revello, M Zavattoni, A Sarasini, et al.
The New Microbiologica
|
November 11, 1999
Diagnostic value of viral culture, polymerase chain reaction and western blot for HIV-1 infection in 218 infants born to HIV-infected mothers and examined at different ages
E Cattaneo, M Zavattoni, F Baldanti, et al.
Journal of Clinical Microbiology
|
June 1, 1990
Serotype 3 human rotavirus strains with subgroup I specificity
G Gerna, A Sarasini, A Di Matteo, et al.
Journal of Virology
|
February 1, 1995
A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate
F Baldanti, E Silini, A Sarasini, et al.
ESMO Open
|
April 15, 2022
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
A Lasagna, F Bergami, D Lilleri, et al.
ESMO Open
|
August 27, 2022
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
A Lasagna, F Bergami, D Lilleri, et al.
ESMO Open
|
January 1, 2022
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
A Lasagna, D Lilleri, F Agustoni, et al.
ESMO Open
|
September 20, 2021
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
A Lasagna, F Agustoni, E Percivalle, et al.
Page
of 6